TC
BSTG

TFS Capital’s Biostage, Inc. Common Stock BSTG Stock Holding History

TFS Capital’s Portfolio BSTG Stock Details BSTG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-23,370
Closed -$244K – 1348
2014
Q2 		$244K Buy
23,370
+58
+0.2% +$494 0.02% 896
2014
Q1 		$211K Buy
+23,312
New +$138K 0.01% 1166

Other funds holding BSTG

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
HSA
Hussman Strategic Advisors Ellicott City, Maryland $463M AUM 16% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TFS Capital's BSTG Position: Q3 2014 in Review

TFS Capital sold out of Biostage, Inc. Common Stock (BSTG) in Q3 2014, closing a stake of 23,370 shares — an estimated $244K sold.

TFS Capital first reported a position in BSTG in Q1 2014 and held it in 2 quarters. The position peaked at $244K in Q2 2014. 43 funds tracked by Wall St. Rank hold BSTG as of Q3 2014.

  • TFS Capital reported no remaining Biostage, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • TFS Capital sold 23,370 Biostage, Inc. Common Stock shares in Q3 2014, an estimated $244K.
  • TFS Capital first reported a position in Biostage, Inc. Common Stock in Q1 2014 and held it in 2 quarters.
  • TFS Capital's Biostage, Inc. Common Stock position peaked at $244K in Q2 2014.
  • 43 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q3 2014.

Based on TFS Capital's 13F filing for Q3 2014, filed 6 Nov 2014.